Perspective Therapeutics (CATX) Free Cash Flow (2010 - 2026)
Perspective Therapeutics (CATX) posted Free Cash Flow of -$31.5 million for Q1 2026, up 15.69% sequentially from -$37.3 million in Q4 2025, and down 19.93% YoY from -$39.3 million in Q1 2025.
Perspective Therapeutics (CATX) Free Cash Flow (2010 - 2026) Analysis & Trends
Perspective Therapeutics has reported Free Cash Flow for 17 years, with the latest figure at -$31.5 million in Q1 2026.
- Quarterly Free Cash Flow fell 19.93% year-over-year to -$31.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$100.5 million (up 10.93% YoY) and the FY2025 annual result came in at -$95.2 million, down 30.98% from the prior year.
- Free Cash Flow grew to -$31.5 million in Q1 2026 per CATX's latest filing, from -$37.3 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $13.8 million in Q1 2024 and troughed at -$41.2 million in Q4 2024.
- A 5-year average of -$15.0 million and a median of -$10.3 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow plunged 584.41% in 2023, then jumped 239.54% in 2024.
- Over 5 years, Free Cash Flow stood at -$6.2 million in 2022, then slumped by 45.86% to -$9.1 million in 2023, then plunged by 353.12% to -$41.2 million in 2024, then climbed by 9.46% to -$37.3 million in 2025, then advanced by 15.69% to -$31.5 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$31.5 million, -$37.3 million, and -$16.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 1.99 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 1.06 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 2.09 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 1.28 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 585.00 Mn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 184.50 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 68.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 511.44 Mn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 279.60 Mn |
| 10 | Perspective Therapeutics | 389.10 Mn | 389.10 Mn | - | -34.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.85 Mn |
| Jun 30, 2026 | -34.85 Mn |
| Mar 31, 2026 | -31.47 Mn |
| Mar 31, 2026 | -31.47 Mn |
| Dec 31, 2025 | -37.32 Mn |
| Dec 31, 2025 | -37.32 Mn |
| Sep 30, 2025 | -16.33 Mn |
| Sep 30, 2025 | -16.33 Mn |
| Jun 30, 2025 | -15.34 Mn |
| Jun 30, 2025 | -15.34 Mn |
| Mar 31, 2025 | -26.24 Mn |
| Mar 31, 2025 | -26.24 Mn |
| Dec 31, 2024 | -41.22 Mn |
| Dec 31, 2024 | -41.22 Mn |
| Sep 30, 2024 | -26.35 Mn |
| Sep 30, 2024 | -26.35 Mn |
| Jun 30, 2024 | -18.99 Mn |
| Jun 30, 2024 | -18.99 Mn |
| Mar 31, 2024 | 13.85 Mn |
| Mar 31, 2024 | 13.85 Mn |